Long-Term Follow-Up Gene Therapy Study for Achromatopsia CNGB3 and CNGA3

Inclusion Criteria

• •Inclusion in the study will be limited to individuals who:
• •1. Are able to give informed consent or assent, with or without the guidance of their parent(s)/guardian(s), where appropriate
• •2. Received AAV2/8-hCARp.hCNGB3 or AAV2/8-hG1.7p.coCNGA3 by intraocular administration in the prior open-label, Phase I/II, dose escalation study (EudraCT 2016-002290-35 or EudraCT 2018-003431-29)
• •3. Are willing to adhere to the protocol and long-term follow-up
• •Individuals will be excluded who:
• •Are unwilling or unable to meet the requirements of the study